ARDS

Therapeutic Solutions Announces Universal Donor Myeloid Derived Suppressor Therapy Platform for Treatment of Chronic Obstructive Pulmonary Disease (COPD)

Retrieved on: 
Monday, November 14, 2022
Science, Stem Cells, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Interleukin, Chronic obstructive pulmonary disease, Cell, Biopharmaceutical, Patent, COVID, TSOI, ARDS, COPD, IND, Inflammation, Pharmaceutical industry

Therapeutic Solutions International (TSOI) announced today new data, licensing, and patent filing on a novel cellular therapy for treatment of Chronic Obstructive Pulmonary Disease (COPD) by its Spin-Off Company Breathe Biologics.

Key Points: 
  • Therapeutic Solutions International (TSOI) announced today new data, licensing, and patent filing on a novel cellular therapy for treatment of Chronic Obstructive Pulmonary Disease (COPD) by its Spin-Off Company Breathe Biologics.
  • The cellular product possessed characteristics of pulmonary progenitor cells combined with immune regulatory myeloid suppressor cells.
  • Breathe Biologics has acquired the IND from Therapeutic Solutions International as part of its initial licensing.
  • Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases.

 Athersys Reports That Its Partner, HEALIOS K.K., Provides Updates on MultiStem® Clinical Programs in Japan

Retrieved on: 
Monday, April 4, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, ISCHEMIC STROKE, ARDS, MULTISTEM, ATHERSYS, HEALIOS

(Healios), has provided updates on its two clinical programs evaluating MultiStem (invimestrocel, HLCM051) cell therapy, for which Healios has a license and is responsible for the development and commercialization of MultiStem for ischemic stroke and acute respiratory distress syndrome (ARDS) in Japan on an exclusive basis.

Key Points: 
  • (Healios), has provided updates on its two clinical programs evaluating MultiStem (invimestrocel, HLCM051) cell therapy, for which Healios has a license and is responsible for the development and commercialization of MultiStem for ischemic stroke and acute respiratory distress syndrome (ARDS) in Japan on an exclusive basis.
  • Athersys expects that the TREASURE 90-day and one-year results would be strong indicators of the potential results from Athersys MASTERS-2 study.
  • The ONE-BRIDGE clinical trial was designed as a 30-patient, open label study, and demonstrated promising impact from MultiStem treatment on ventilator free days (VFD) and mortality.
  • Athersys plans to work closely with Healios to build the supporting data necessary to apply for approval in Japan, including exploring the possibility of using certain MACOVIA clinical data.

First-of-its-kind Medical Technology Patent Issued Enabling Non-invasive Ventilation (NIV) Patients to Communicate Without Mask Removal

Retrieved on: 
Tuesday, March 8, 2022
CHF, Centers for Medicare & Medicaid Services, Patient, Risk, Compliance, SALT, Department, Company, Communication, Failure, United States Department of Health and Human Services, NIV, CMS, Heart failure, Failure rate, Chronic obstructive pulmonary disease, DHHS, Face, Phlegm, Xerostomia, DSP, CPAP, Human, United States patent law, Technology, Solution, Joint Commission, COPD, Method, Medicare, Frustration, Patent, Accreditation, Atmosphere, Oxygen, ARDS, JCAHO, Research Institute of Healthcare Organization and Medical Management of Moscow Department of Healthcare, Caregiver, Controller, PPV, Center, Pharmaceutical industry, Medicine

11,222,648 has been issued by the US Patent Office covering a positive pressure ventilation (PPV) microphone system, nebulizer, and related methods.

Key Points: 
  • 11,222,648 has been issued by the US Patent Office covering a positive pressure ventilation (PPV) microphone system, nebulizer, and related methods.
  • ReddyPort Microphone with integrated speaker uses (DSP) digital signal processing to remove breathing noises and naturalize the patient's voice.
  • "ReddyPort Microphone is an essential device designed to empower patients with the ability to communicate to caregivers and family members.
  • ReddyPort provides solutions for NIV patients to improve satisfaction, reduce risk and cost, enable better workflows, and enhance quality of care.

Drug halts immune reactions to save damaged lungs

Retrieved on: 
Tuesday, February 8, 2022
CT, Biomedical Research, NETS, Mouse, Multimedia, Icahn School of Medicine at Mount Sinai, Cell, Immune system, Cancer, Infection, Student, FDA, Neuroscience, Patient, CSHL, Transfusion-related acute lung injury, WCM, Disulfiram, Survival, Weill Cornell Medicine, ARDS, Blood, SPRING, Laboratory, DNA, Google Images, Edema, Poison, Cold Spring Harbor Laboratory, Mount Sinai, Nobel Prize, American Society for Clinical Investigation, NET, Acute respiratory distress syndrome, Education, Neutrophil, COVID-19, Pharmaceutical industry

To extend their reach, neutrophils spew a sticky web of DNA and toxins, which indiscriminately poisons pathogens and the body's own cells.

Key Points: 
  • To extend their reach, neutrophils spew a sticky web of DNA and toxins, which indiscriminately poisons pathogens and the body's own cells.
  • Because NETs can be so destructive, researchers in Egeblad's lab have been searching for ways to block their formation.
  • Disulfiram, which has been used since the 1950s as a treatment for alcohol use disorders, was a promising candidate.
  • Home to eight Nobel Prize winners, the private, not-for-profit Laboratory employs 1,100 people including 600 scientists, students and technicians.

Endpoint Health Presents Published Results from a Retrospective Study of Adult ARDS Patients, Identifying an Innovative Approach to Predicting Clinical Outcomes

Retrieved on: 
Thursday, January 6, 2022
Biotechnology, Health, Clinical Trials, Other Health, OH, Blood gas tension, Blood, Genetically modified bacteria, Safety, Rajneesh Duggal, Oxygen, Health, Fraction of inspired oxygen, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Respiratory rate, Doctor of Philosophy, Â, Therapy, Review, Inhalation, Research, Injury, Patient, Adult, Bilirubin, Ventilation, Cleveland Clinic, BMJ, BMJ Open, Acute pancreatitis, Sepsis, Social, Partial pressure, Twitter, American Thoracic Society, Disease, MD, Department, Cleveland, Creatinine, Inflammation, Mortality, Rheumatoid arthritis, Endpoint, Heart rate, Chest injury, Social media, Pneumonia, Survivor, Critical Care Medicine (journal), Acute respiratory distress syndrome, Pharmaceutical industry, Medical imaging, Medical device, Dietary supplement, the Study, ARDS, Endpoint Health, THE STUDY, ARDS, ENDPOINT HEALTH

The clinical utility of subphenotypic assessment in ARDS would require validation in a prospective clinical study.

Key Points: 
  • The clinical utility of subphenotypic assessment in ARDS would require validation in a prospective clinical study.
  • In current clinical practice, risk stratification for patients with ARDS solely depends on the PaO2/FiO2 clinical measure.
  • The retrospective analysis drew on data from six randomized clinical trials in adult patients with ARDS (five U.S. and one international study).
  • Identification of acute respiratory distress syndrome subphenotypes de novo using routine clinical data: a retrospective analysis of ARDS clinical trials.

Gb Sciences Targets COVID-19 Treatment as Omicron Variant Arrives

Retrieved on: 
Monday, December 6, 2021
Patient, University, Heart failure, Contract, Coronavirus, Anxiety, CCCM, Biomarker, Michigan, CRS, Death, Hospital, Macrophage activation syndrome, Good manufacturing practice, Therapy, MAS, COVID-19, Chronic pain, Cytokine release syndrome, ARDS, Cytokine, Omicron, Research, GLOBE, Depression, MCAS, Parkinson's disease, Michigan State University, Immune system, Acute respiratory distress syndrome, Disease, COVID, Syndrome, Pharmaceutical industry, Vaccine

The preclinical data indicates that the CCCMs may be effective anti-inflammatory therapies for CRS and other conditions such as macrophage activation syndrome (MAS) and acute respiratory distress syndrome (ARDS)-- all leading causes of death in COVID-19 patients.

Key Points: 
  • With reports of the arrival of the Omicron variant of the coronavirus in multiple countries, the Gb Sciences team plans to move quickly through the development stages for this novel CRS therapy.
  • "COVID variants are not going away anytime soon, and they will continue to cause health complications, particularly in unvaccinated individuals and older populations," said Dr. Andrea Small-Howard, President and Chief Science Officer of Gb Sciences.
  • Gb Sciences' novel drug discovery platform has yielded three issued U.S. patents, as well as 8 U.S. and 39 international pending patent applications.
  • GB Sciences' productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations.

Report of Placebo-Controlled Clinical Trial Evaluating MultiStem® Cell Therapy for Acute Respiratory Distress Syndrome Published in Intensive Care Medicine

Retrieved on: 
Tuesday, November 30, 2021
Technology, Manufacturing, Other Health, Health, General Health, Other Science, Other Technology, Research, Other Manufacturing, Science, Clinical Trials, ARDS, MultiStem, Athersys, ARDS, MULTISTEM, ATHERSYS

Athersys, Inc. (NASDAQ: ATHX) announced today that a manuscript reporting data from the Companys MUST-ARDS clinical trial have been published in the peer-reviewed journal Intensive Care Medicine.

Key Points: 
  • Athersys, Inc. (NASDAQ: ATHX) announced today that a manuscript reporting data from the Companys MUST-ARDS clinical trial have been published in the peer-reviewed journal Intensive Care Medicine.
  • MUST-ARDS was a randomized, double-blind placebo-controlled Phase 1/2 trial evaluating the safety and efficacy of MultiStem (invimestrocel) cell therapy in patients with acute respiratory distress syndrome (ARDS).
  • These pooled randomized data sets include 40 non-COVID ARDS patients treated with MultiStem cell therapy and 20 ARDS patients treated with placebo or receiving standard of care.
  • Athersys has forged strategic partnerships and a broad network of collaborations to further advance the MultiStem cell therapy toward commercialization.

NRx Pharmaceuticals Identifies Significantly Higher Likelihood of Surviving and Recovering from Critical COVID-19 in ZYESAMI® (aviptadil) Treated Patients Previously Administered Remdesivir

Retrieved on: 
Monday, November 29, 2021
Lung, Company, National Security Advisor (United States), Doctor of Philosophy, BARDA, JD, GLOBE, Letter, Biotechnology, Development, Israel Institute for Biological Research, Data monitoring committee, Human services, Food, COVID, CEO, Proning, NIH, United States Army, Death, Critical, Hospital, ARDS, Harvard University, Harvard Medical School, Biomedical Advanced Research and Development Authority, National, Principal, Biology, Health, Clinical trial, MPH, Goal, ICU, Acute, Survival, J&J, Fast Track, FDA, EUA, Patient, Dark Enlightenment, US Foods, Breakthrough therapy, Novartis, NCT, ASPE, BTD, COVID-19, Lilly, Nasdaq, Clinical, Public health, Aviptadil, Pharmaceutical industry

Dr. Schoenfeld analyzed the subgroup of patients in the COVID-AIV trial (NCT 04311697) that remained in respiratory failure despite treatment with remdesivir.

Key Points: 
  • Dr. Schoenfeld analyzed the subgroup of patients in the COVID-AIV trial (NCT 04311697) that remained in respiratory failure despite treatment with remdesivir.
  • Based on FDAs input, NRx has narrowed its requested BTD indication to Treatment of COVID-19 Respiratory Failure in patients who progress despite treatment with remdesivir and other approved therapies.
  • NRx Pharmaceuticals (NRx) draws upon more than 300 years of collective, scientific, and drug-development experience to bring improved health to patients.
  • The company assumes no obligation to revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

Athersys Partner HEALIOS K.K. Announces Positive Topline Results of MultiStem for Acute Respiratory Distress Syndrome in the ONE-BRIDGE Study

Retrieved on: 
Friday, August 6, 2021
Biotechnology, General Health, Pharmaceutical, Health, Industry, Interim, Company, NK, Private Securities Litigation Reform Act, COVID, Acute respiratory distress syndrome, Clinical trial, Mortality, Regenerative medicine, Safety, Stroke, United Kingdom, Convalescence, B cell, Population, Infection, Environment, COVID-19, Rehabilitation, NASDAQ, Technology, Biotechnology, Makó, Patient, Inflammation, Trauma, University of Texas System, Disease, Injury, Annual report, Sepsis, ICU, SEC, VFD, Twitter, Quality of life, Pneumonia, Patent, Therapy, Tokyo Stock Exchange, IPSC, TSE, University, Gene editing, Mother, Face, Pharmaceutical industry, ARDS, MultiStem, Athersys, Healios:, ARDS, MULTISTEM, ATHERSYS, HEALIOS:

(Healios), has released positive topline data from its ONE-BRIDGE clinical trial evaluating the safety and efficacy of MultiStem cell therapy (invimestrocel) in patients with acute respiratory distress syndrome (ARDS).

Key Points: 
  • (Healios), has released positive topline data from its ONE-BRIDGE clinical trial evaluating the safety and efficacy of MultiStem cell therapy (invimestrocel) in patients with acute respiratory distress syndrome (ARDS).
  • "We are excited by the results reported by our partner, Healios," commented Mr. William (B.J.)
  • Athersys is currently conducting its MACoVIA study, a double-blind, placebo-controlled study evaluating MultiStem administration in patients with ARDS resulting from COVID-19 and other pathogens.
  • Acute respiratory distress syndrome (ARDS) is a serious immunological and inflammatory condition characterized by widespread inflammation in the lungs.

Athersys Reports That Healios Has Completed Enrollment in the ONE-BRIDGE Study of MultiStem® for Acute Respiratory Distress Syndrome in Japan

Retrieved on: 
Wednesday, March 31, 2021
Health, Stem cells, Other Health, Clinical trials, Research, Science, Biotechnology, Medical specialties, Clinical medicine, Medicine, Intensive care medicine, Respiratory diseases, Acute respiratory distress syndrome, Respiratory physiology, Ards, Respiratory distress syndrome, Infant respiratory distress syndrome, Pathophysiology of acute respiratory distress syndrome, Carolyn Calfee, ARDS, MultiStem, Athersys, Healios

(Healios) has completed enrollment in the ONE-BRIDGE study in Japan evaluating MultiStem (invimestrocel) in patients with acute respiratory distress syndrome (ARDS) caused by pneumonia.

Key Points: 
  • (Healios) has completed enrollment in the ONE-BRIDGE study in Japan evaluating MultiStem (invimestrocel) in patients with acute respiratory distress syndrome (ARDS) caused by pneumonia.
  • Healios intends to analyze and evaluate the data after the follow-up period and will make further announcements, as appropriate.
  • In the United States, Athersys is conducting its own clinical study evaluating MultiStem cell therapy for the treatment of ARDS, the MACOVIA trial.
  • Acute respiratory distress syndrome (ARDS) is a serious immunological and inflammatory condition characterized by widespread inflammation in the lungs.